Pilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 30 Apr 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 30 Jan 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.